A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

Summary

The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer including screening.

Eligibility

Inclusion Criteria:

* Has been treated for the following blood cancers and has received at least 2 prior lines of systemic therapy or not eligible for available therapy:

  * Diffuse large B-cell lymphoma - not otherwise specified
  * High-grade B-cell lymphoma
  * Diffuse large B-cell lymphoma - transformed from indolent lymphomas
  * Follicular large B-cell lymphoma
  * Follicular lymphoma
  * Other non-Hodgkin lymphoma
* Has measurable disease
* Has discontinued all previous treatments for cancer and has recovered from the immediate effects of therapy

Exclusion Criteria:

* Has an active second cancer
* Has known central nervous system (CNS) involvement by systemic lymphoma. Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of active CNS disease may be eligible and enrolled if a compelling clinical rationale is provided by the Investigator and with documented Sponsor approval.
* Has known Cytomegalovirus infection. Participants with negative status are eligible
* Has known hepatitis B or C infection or uncontrolled HIV
* Has known significant heart disease

Conditions4

Interventions2

Locations21 sites

Find trials near these locations

Related trials

• A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL — InnoCare Pharma Inc.
• A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma — University of Birmingham
• A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors — LaNova Medicines Limited
• A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors — BeOne Medicines
• A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) — Dizal (Jiangsu) Pharmaceutical Co., Ltd.
• A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma — Guangzhou Lupeng Pharmaceutical Company LTD.
• A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma — Second Affiliated Hospital, School of Medicine, Zhejiang University
• A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma — Ruijin Hospital

Browse More Trials